CSL struck a co-development deal with Alentis Therapeutics for an anti-fibrosis program spanning kidney and liver indications, agreeing to a $355 million upfront payment and additional milestone funding up to $1.2 billion. The arrangement is designed to advance shared development, pairing CSL’s execution capacity with Alentis’ candidate. For biotech, the headline is the scale of the upfront and milestone structure—an indicator that fibrosis remains a high-priority area for large pharma and that private-company stage programs are drawing major balance-sheet commitments. The deal also underscores continued interest in organ-fibrosis strategies where disease-modifying endpoints remain difficult, but partnerships can accelerate patient exposure and regulatory planning.